Skip to Content
Merck
  • Mycophenolic acid mediated disruption of the intestinal epithelial tight junctions.

Mycophenolic acid mediated disruption of the intestinal epithelial tight junctions.

Experimental cell research (2014-02-11)
Muhammad Qasim, Hazir Rahman, Raees Ahmed, Michael Oellerich, Abdul R Asif
ABSTRACT

Gastrointestinal toxicity is a common adverse effect of mycophenolic acid (MPA) treatment in organ transplant patients, through poorly understood mechanisms. Phosphorylation of myosin light chain 2 (MLC2) is associated with epithelial tight junction (TJ) modulation which leads to defective epithelial barrier function, and has been implicated in GI diseases. The aim of this study was to investigate whether MPA could induce epithelial barrier permeability via MLC2 regulation. Caco-2 monolayers were exposed to therapeutic concentrations of MPA, and MLC2 and myosin light chain kinase (MLCK) expression were analyzed using PCR and immunoblotting. Epithelial cell permeability was assessed by measuring transepithelial resistance (TER) and the flux of paracellular permeability marker FITC-dextran across the epithelial monolayers. MPA increased the expression of MLC2 and MLCK at both the transcriptional and translational levels. In addition, the amount of phosphorylated MLC2 was increased after MPA treatment. Confocal immunofluorescence analysis showed redistribution of TJ proteins (ZO-1 and occludin) after MPA treatment. This MPA mediated TJ disruption was not due to apoptosis or cell death. Additionally ML-7, a specific inhibitor of MLCK was able to reverse both the MPA mediated decrease in TER and the increase in FITC-dextran influx, suggesting a modulating role of MPA on epithelial barrier permeability via MLCK activity. These results suggest that MPA induced alterations in MLC2 phosphorylation and may have a role in the patho-physiology of intestinal epithelial barrier disruption and may be responsible for the adverse effects (GI toxicity) of MPA on the intestine.

MATERIALS
Product Number
Brand
Product Description

Dextran 4 for calibration, Dextran 4 European Pharmacopoeia (EP) Reference Standard
Supelco
Dextran from Leuconostoc mesenteroides, for GPC, analytical standard, Mw 50,000
Supelco
Dextran, analytical standard, for GPC, Set Mp 1,000-400,000
Supelco
Dextran from Leuconostoc mesenteroides, analytical standard, for GPC, Mw 5,000
Supelco
Dextran from Leuconostoc mesenteroides, analytical standard, for GPC, Mw 12,000
Dextran 1, Dextran 1 European Pharmacopoeia (EP) Reference Standard
Dextran Vo, Dextran Vo European Pharmacopoeia (EP) Reference Standard
Supelco
Mycophenolic acid solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Dextran, analytical standard, for GPC, 12,000
Supelco
Dextran, analytical standard, for GPC, 150,000
Supelco
Dextran, analytical standard, for GPC, 670,000
Supelco
Dextran, analytical standard, for GPC, 1,000
Supelco
Dextran, analytical standard, for GPC, 80,000
Supelco
Dextran, analytical standard, for GPC, 50,000
Supelco
Dextran, analytical standard, for GPC, 410,000
Sigma-Aldrich
Dextran from Leuconostoc spp., Mr 15,000-25,000
Supelco
Dextran, analytical standard, for GPC, 5,000
Supelco
Dextran, analytical standard, for GPC, 25,000
Supelco
Dextran, analytical standard, for GPC, 270,000
Sigma-Aldrich
Dextran from Leuconostoc mesenteroides, Mr ~60,000
Sigma-Aldrich
Dextran from Leuconostoc spp., Mr ~70,000
Sigma-Aldrich
Dextran, enzymatic synth.
Sigma-Aldrich
Dextran from Leuconostoc spp., Mr 450,000-650,000
Sigma-Aldrich
Dextran from Leuconostoc spp., Mr ~6,000
Sigma-Aldrich
Dextran from Leuconostoc mesenteroides, Mr ~200,000
Sigma-Aldrich
Dextran from Leuconostoc spp., Mr ~100,000
Sigma-Aldrich
Dextran from Leuconostoc spp., Mr ~40,000
Supelco
Dextran from Leuconostoc mesenteroides, analytical standard, for GPC, Mw 1,000
Sigma-Aldrich
Dextran from Leuconostoc mesenteroides, average mol wt 35,000-45,000
Sigma-Aldrich
Dextran from Leuconostoc mesenteroides, average mol wt 1,500,000-2,800,000